What's interesting about inequitable conduct is that it's considered the atomic bomb of patent law. These are not my words, this is actually Chief Judge Rader who called it "the atomic bomb of ...

It will come as no surprise to patent practitioners that they must disclose to the U.S. Patent and Trademark Office (PTO) all relevant references, e.g., published articles, that are known to them.

For example, in Regeneron Pharms, the Court upheld a finding of inequitable conduct based on an adverse inference of intent arising from post-prosecution and litigation misconduct.[3] In Gilead v.

In Aventis Pharma SA v Hospira Inc (2012), the court affirmed a pre-Therasense judgment of inequitable conduct rendered after a bench trial. In Aventis, the references were but-for material because ...

In its first post-Therasense case (seeIP Update, Vol. 14, No. 6) addressing the issue of inequitable conduct, the U.S.

Throughout its investigation, the league determined that Sarver used the N-word on five different occasions, engaged in instances of inequitable conduct toward female employees, and made ...

It will come as no surprise to patent practitioners that they must disclose to the U.S. Patent and Trademark Office (PTO) all relevant references, e.g., published articles, that are known to them.